Safety & Efficacy of Baclofen for Alcohol Withdrawal in Chronic Liver Disease With Active Alcohol Consumption
Launched by CORPORACION PARC TAULI · Feb 20, 2025
Trial Information
Current as of June 26, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
The medical management of alcohol use disorder (AUD) requires a multidisciplinary approach, involving psychiatrists, psychologists, and hepatologists. Treatment often combines pharmacotherapy with psychosocial interventions to achieve and maintain abstinence. Over the years, various anti-craving medications have been used. Due to its renal metabolism, rather than hepatic, baclofen is considered safe for individuals with chronic liver disease and is currently the first-line pharmacological agent for patients with AUD and secondary liver disease.
Despite clinical guidelines recommending bacl...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients with chronic liver disease at any stage
- • Active alcohol consumption
- • Use of baclofen for the treatment of alcohol dependence.
- Exclusion Criteria:
- • Severe psychiatric illness requiring other psychotropic pharmacological treatments
- • Organic or functional renal insufficiency
About Corporacion Parc Tauli
Corporación Parc Taulí is a leading healthcare organization based in Sabadell, Spain, known for its commitment to advancing medical research and clinical excellence. With a focus on innovative healthcare solutions, the organization integrates cutting-edge technology and multidisciplinary collaboration to enhance patient outcomes. As a sponsor of clinical trials, Corporación Parc Taulí emphasizes ethical practices, rigorous scientific methodologies, and robust data management to contribute to the development of new therapies and improve healthcare standards. Their dedication to research and patient care positions them as a vital player in the clinical research landscape.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Sabadell, Barcelona, Spain
Patients applied
Trial Officials
Jordi Sánchez Delgado, MD. PhD
Principal Investigator
Consorci Corporació Sanitària Parc Taulí
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported